Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for AMNEAL PHARMACEUTICALS, INC. (AMRX : NSDQ)
 
 • Company Description   
Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories Inc., is based in New Jersey, United States.

Number of Employees: 8,100

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.39 Daily Weekly Monthly
20 Day Moving Average: 1,618,210 shares
Shares Outstanding: 313.42 (millions)
Market Capitalization: $2,629.59 (millions)
Beta: 1.06
52 Week High: $9.48
52 Week Low: $6.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 5.40% 1.45%
12 Week 13.99% -4.12%
Year To Date 5.93% -0.79%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
400 CROSSING BOULEVARD
-
BRIDGEWATER,NJ 08807
USA		 ph: 908-947-3120
fax: 908-947-3146		 anthony.dimeo@amneal.com http://www.amneal.com
 
 • General Corporate Information   
Officers
Chirag Patel - Co- Chief Executive Officer and President
Emily Peterson Alva - Chairman
Anastasios Konidaris - Executive Vice President; Chief Financial Officer
Emily Peterson Alva - Director
Deb Autor - Director

Peer Information
AMNEAL PHARMACEUTICALS, INC. (GSAC)
AMNEAL PHARMACEUTICALS, INC. (CASI)
AMNEAL PHARMACEUTICALS, INC. (ALCD.)
AMNEAL PHARMACEUTICALS, INC. (OMNN)
AMNEAL PHARMACEUTICALS, INC. (CGPI.)
AMNEAL PHARMACEUTICALS, INC. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 03168L105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 313.42
Most Recent Split Date: (:1)
Beta: 1.06
Market Capitalization: $2,629.59 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.16 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.64 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 13.18
Trailing 12 Months: 14.22
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: 6.04
Price / Sales: 0.93
EPS Growth
vs. Year Ago Period: 58.33%
vs. Previous Quarter: 90.00%
Sales Growth
vs. Year Ago Period: 5.50%
vs. Previous Quarter: -4.80%
ROE
06/30/25 - -
03/31/25 - -188.26
12/31/24 - -202.85
ROA
06/30/25 - -
03/31/25 - 5.34
12/31/24 - 4.72
Current Ratio
06/30/25 - -
03/31/25 - 1.40
12/31/24 - 1.41
Quick Ratio
06/30/25 - -
03/31/25 - 0.84
12/31/24 - 0.86
Operating Margin
06/30/25 - -
03/31/25 - 6.53
12/31/24 - 5.88
Net Margin
06/30/25 - -
03/31/25 - -0.46
12/31/24 - -4.18
Pre-Tax Margin
06/30/25 - -
03/31/25 - 2.05
12/31/24 - -1.97
Book Value
06/30/25 - -
03/31/25 - -0.42
12/31/24 - -0.35
Inventory Turnover
06/30/25 - -
03/31/25 - 3.00
12/31/24 - 3.01
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©